SINCE THE FIRST BLOOD-BASED, circulating-tumor DNA (ctDNA) sequencing test for cancer became available in 2014, federal and private payer coverage of these so-called “liquid biopsy” tests has increased substantially. Now, clinical laboratory and pathology directors can expect additional coverage as the clinical utility of these assays becomes more widely accepted. The lead author of a […]
- Managed Care Update
Payers Continue to Increase Coverage of Liquid Biopsies
Research team expects greater reimbursement as clinicians expand their use of ctDNA tests
- By Robert Michel
- > From the Volume XXVIII, No. 17 - December 20, 2021 Issue
- Tags: American Lung Association, Blue Cross Blue Shield Massachusetts, CDx liquid biopsy test, Center for Translational and Policy Research on Precision Medicine, circulating-tumor DNA, circulating-tumor-cell test, cobas EGFR Mutation Test v2, Companion diagnostics, ctDNA, ctDNA-based panel test, DL37810, EGFR, epidermal growth factor receptor, FDA, Food and Drug Administration, FoundationOne Liquid CDx, Guardant360, Guardiant360 CDx, JNCCN, Journal of the National Comprehensive Cancer Network, Kyle Fetter, L38290, LCD, liquid biopsy, local coverage determination, MAC, managed care, MD Anderson Cancer Center, Medicare Administrative Contractor, Medicare Administrative Contractors, Michael Douglas, Natera Inc., National Comprehensive Cancer Network, national coverage determination, National Government Services, National Institutes of Health, NCD 90.2, next generation sequencing, non-small cell lung cancer, NSCLC, OncoBEAM, plasma biopsies, roche molecular diagnostics, University of California San Francisco, xifin, Yale Medicine
